KR20250006156A - 파르네소이드 x 수용체 효능제의 용도 - Google Patents

파르네소이드 x 수용체 효능제의 용도 Download PDF

Info

Publication number
KR20250006156A
KR20250006156A KR1020247038272A KR20247038272A KR20250006156A KR 20250006156 A KR20250006156 A KR 20250006156A KR 1020247038272 A KR1020247038272 A KR 1020247038272A KR 20247038272 A KR20247038272 A KR 20247038272A KR 20250006156 A KR20250006156 A KR 20250006156A
Authority
KR
South Korea
Prior art keywords
patient
compound
score
pharmaceutically acceptable
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247038272A
Other languages
English (en)
Korean (ko)
Inventor
토마스 카포자
Original Assignee
인터셉트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터셉트 파마슈티컬즈, 인크. filed Critical 인터셉트 파마슈티컬즈, 인크.
Publication of KR20250006156A publication Critical patent/KR20250006156A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020247038272A 2022-04-21 2023-04-21 파르네소이드 x 수용체 효능제의 용도 Pending KR20250006156A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333287P 2022-04-21 2022-04-21
US63/333,287 2022-04-21
US202263381752P 2022-10-31 2022-10-31
US63/381,752 2022-10-31
PCT/US2023/019448 WO2023205447A2 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Publications (1)

Publication Number Publication Date
KR20250006156A true KR20250006156A (ko) 2025-01-10

Family

ID=88420596

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247038272A Pending KR20250006156A (ko) 2022-04-21 2023-04-21 파르네소이드 x 수용체 효능제의 용도

Country Status (10)

Country Link
US (1) US20250288600A1 (https=)
EP (1) EP4511012A2 (https=)
JP (1) JP2025513289A (https=)
KR (1) KR20250006156A (https=)
CN (1) CN119136794A (https=)
AU (1) AU2023257308A1 (https=)
CA (1) CA3249500A1 (https=)
IL (1) IL315941A (https=)
MX (1) MX2024012966A (https=)
WO (1) WO2023205447A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4611888A1 (en) * 2022-10-31 2025-09-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
ES2874682T3 (es) * 2016-03-11 2021-11-05 Intercept Pharmaceuticals Inc Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
BR112019027458A2 (pt) * 2017-06-23 2020-07-07 Intercept Pharmaceuticals, Inc. métodos e intermediários para a preparação de derivados de ácidos biliares

Also Published As

Publication number Publication date
WO2023205447A3 (en) 2024-04-04
US20250288600A1 (en) 2025-09-18
CA3249500A1 (en) 2023-10-26
WO2023205447A2 (en) 2023-10-26
MX2024012966A (es) 2024-11-08
EP4511012A2 (en) 2025-02-26
JP2025513289A (ja) 2025-04-24
IL315941A (en) 2024-11-01
AU2023257308A1 (en) 2024-10-10
CN119136794A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
Rautiainen et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three‐year randomized trial
JP2021063088A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
Tauchmanovà et al. Andrenocortical carcinomas: twelve-year prospective experience
Dreon et al. Oral contraceptive use and increased plasma concentration of C-reactive protein
JP2020147585A (ja) 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
Felicetti et al. Cancer survivors: an expanding population with an increased cardiometabolic risk
Talwalkar et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis
Gammon et al. CD8+ granulomatous cutaneous T-cell lymphoma: A potential association with immunodeficiency
JP2022516509A (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
Kotsopoulos et al. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
Guazzelli et al. Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism
Zhang et al. UBE2J1 knockdown promotes cell apoptosis in endometrial cancer via regulating PI3K/AKT and MDM2/p53 signaling
US20250288600A1 (en) Uses of farnesoid x receptor agonists
KR20200017487A (ko) 비알코올성 지방간염 치료를 위한 리코플리고진
EP4611888A1 (en) Uses of farnesoid x receptor agonists
Alkhunaizi et al. Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus
US20230000832A1 (en) Use of neuropilin antagonists for the treatment of endometriosis
CN115605198B (zh) 脂肪性肝病的治疗药
WO2019246107A1 (en) Metabolic biomarkers of nafld/nash and related disease phenotypes and methods of using same
Pagán et al. Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage
Soine et al. A patient with coexistent bullous pemphigoid and primary membranous glomerulonephropathy
Rozmus et al. Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores
Furini et al. Ketogenic state is able to improve testosterone serum levels-a meta-analytic approach
HK40080642A (en) Therapeutic agent for fatty liver disease
Lee et al. Changes in Insulin-like Growth Factor-1 Level in Patients with Sepsis and Septic Shock

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000